Table 2.

A. Survival analysis (disease-specific survival). Chemotherapy-naive population. Univariate and multivariate analysis.

		Univariate analysis		Multivariate analysis
115 triple-negative breast cancer patients		DS-survival HR [95% CI]	p value	DS-survival HR [95% CI]	p value
Menopausal status	Pre	1
	Post	1.31 [0.56-3.06]	0.53
Tumor size (mm)	<20 mm	1
	>20 mm	2.36 [1.01-5.48]	0.04
Tumor grade	I-II	1
	III	1.33 [0.51-3.49]	0.56
Lymph node status	0	1
	1	3.66 [1.65-8.11]	0.001
NPI score	<3.4	1		1
	3.4-5.4	1.36 [0.47-3.96]	0.57	1.55 [0.53-4.51]	0.43
	>5.4	10.69 [2.74-41.76]	0.001	12.03 [3.05-47.50]	0.0004
Cellularity	Low	1
	Moderate	1.91 [0.54-6.71]	0.31
	High	1.42 [0.41-4.90]	0.58
P53 status	Wild-type	1
	Mutant	0.90 [0.17-4.63]	0.90
Immunity1 metagene expression	High	1
	Low	1.56 [0.76-3.19]	0.22
Immunity2 metagene expression	High	1		1
	Low	2.33 [1.09-4.95]	0.03	2.42 [1.13-5.16]	0.02
Proliferation/DNA damage metagene expression	High	1
	Low	1.14 [0.56-2.32]	0.72
AR-like metagene expression	High	1
	Moderate	0.96 [0.42-2.20]	0.92
	Low	0.74 [0.28-2.00]	0.56
Matrix/Invasion1 metagene expression	High	1
	Low	0.48 [0.23-1.01]	0.06
Matrix2 metagene expression	High	1
	Low	1.31 [0.64-2.66]	0.46

Abbreviations: NPI, Nottingham Prognostic Index; AR, androgen receptor; HR, hazard ratio; CI, confidence interval.